Understanding the Personal Impact of Substance Use Disorders (including Opioid Use Disorder)

与公众的有效接触对于扩大美国食品和药物管理局的影响至关重要。 药品监督管理局，并在机构之间有效地传递信息和见解， 患者、学术界、消费者和受监管行业。通过“支持：支持患者 访问，真实世界的证据，和关键的合作”，里根-尤德尔基金会 FDA将扩大我们的活动，使FDA之间的关键公共卫生合作， 工业和公众。根据国会的具体意图，我们将确定未满足的监管要求， 科学需要和支持的项目和计划，促进使用最新的 生物医学研究和开发，以实现产品开发现代化，加速 创新，提高产品安全性。 数据库有三个具体目标：1）支持真实世界的数据和证据; 2）增强 获得研究药物; 3）加强营养教育和 食品安全 在目标1中，基金会将开发一个真实世界数据联盟，作为一个平台， 评估和进行算法验证研究，并验证基于索赔的算法， 高度优先的健康成果。此外，基金会将召集不同的利益攸关方， 投资于使用真实世界的数据来分享通过COVID-19获得的发现和经验教训 Evidence Accelerator平台Evidence Accelerator将有助于描述自然 COVID-19的历史，并生成与COVID-19的安全性和有效性相关的证据 治疗学 在目标2中，基金会将利用其在扩大获取方面的专门知识和经验， 患者参与，以提高认识，并协助处方医生和患者， 申请扩大准入的混乱过程。一个新的扩展访问应用程序 提交门户将被整合到基金会的扩展访问导航器中， 简化林业发展局工作人员对申请的处理。新的医疗保健用户指南和工具包 将通过我们的利益相关者网络开发和传播提供者和患者。 最后，在目标3中，我们将利用我们的专门知识召集各种团体，发展伙伴关系 为FDA和食品利益相关者分享观点创造新的机会， 就营养和食品安全相关的重要问题进行合作。作为第一项活动， 伙伴关系将侧重于建立一个教育运动，以促进使用和了解 修订后的营养成分标签。

Effective engagement with the public is essential to expand the impact of the U.S. Food and Drug Administration, and for the efficient transfer of information and insights among the agency, patients, academia, consumers and regulated industry. Through “SPARC: Supporting Patient Access, Real-world evidence, and critical Collaborations”, the Reagan-Udall Foundation for the FDA will expand our activities that enable critical public health collaborations among FDA, industry, and the public. As specifically intended by Congress, we will identify unmet regulatory science needs and support projects and programs that promote the use of the latest in biomedical research and development to modernize product development, accelerate innovation, and enhance product safety. SPARC has three Specific Aims: 1) Supporting Real-World Data and Evidence; 2) Enhancing Access to Investigational Medications; and 3) Partnerships to Enhance Nutrition Education & Food Safety. In Aim 1, the Foundation will develop a real-world data consortium to serve as a platform to evaluate and conduct algorithm validation studies and to validate claims-based algorithms for high priority health outcomes. In addition, the Foundation will convene diverse stakeholders invested in using real-world data to share findings and lessons learned through the COVID-19 Evidence Accelerator platform The Evidence Accelerator will help to characterize the natural history of COVID-19 and generate evidence related to the safety and effectiveness of COVID-19 therapeutics. In Aim 2, the Foundation will leverage its expertise and experience in expanded access and patient engagement to increase awareness and assist prescribers and patients in the often- confusing process of applying for expanded access. A new Expanded Access Application Submission Portal will be integrated into the Foundation’s Expanded Access Navigator to simplify the processing of requests by FDA staff. New user guides and toolkits for healthcare providers and patients will be developed and disseminated through our stakeholder network. Finally, in Aim 3, we will use our expertise in convening diverse groups to develop a partnership to create new opportunities for FDA and food stakeholders to share perspectives and collaborate on important issues related to nutrition and food safety. As a first activity, the partnership will focus on building an education campaign to promote the use and understanding of the revised Nutrition Facts Label.